GB9507298D0
(en)
*
|
1995-04-07 |
1995-05-31 |
Pharmacia Spa |
Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
|
US6846839B1
(en)
|
1995-06-07 |
2005-01-25 |
Sugen, Inc. |
Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
|
US6316635B1
(en)
|
1995-06-07 |
2001-11-13 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
US6906093B2
(en)
|
1995-06-07 |
2005-06-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
US6147106A
(en)
|
1997-08-20 |
2000-11-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
US5880141A
(en)
*
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
US6716575B2
(en)
|
1995-12-18 |
2004-04-06 |
Sugen, Inc. |
Diagnosis and treatment of AUR1 and/or AUR2 related disorders
|
US7119174B2
(en)
|
1995-12-18 |
2006-10-10 |
Sugen, Inc. |
Diagnosis and treatment of AUR1 and/or AUR2 related disorders
|
GB9610964D0
(en)
*
|
1996-05-24 |
1996-07-31 |
Pharmacia & Upjohn Spa |
Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors
|
US6696448B2
(en)
|
1996-06-05 |
2004-02-24 |
Sugen, Inc. |
3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
|
GB9611797D0
(en)
*
|
1996-06-06 |
1996-08-07 |
Pharmacia Spa |
Substituted quinolylmethylen-oxindole analogues as tyrosine kinase inhibitors
|
AU4155697A
(en)
*
|
1996-08-23 |
1998-03-06 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
AU7622698A
(en)
*
|
1996-12-05 |
1998-06-29 |
Sugen, Inc. |
Use of indolinone compounds as modulators of protein kinases
|
ES2384551T3
(es)
*
|
1997-03-05 |
2012-07-06 |
Sugen, Inc. |
Formulaciones para agentes farmacéuticos hidrófobos
|
WO1998045708A1
(en)
*
|
1997-04-08 |
1998-10-15 |
Sugen, Inc. |
Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
|
US6818440B2
(en)
|
1997-04-28 |
2004-11-16 |
Sugen, Inc. |
Diagnosis and treatment of alk-7 related disorders
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
ATE292623T1
(de)
*
|
1997-05-07 |
2005-04-15 |
Sugen Inc |
2-indolinonderivate als modulatoren der proteinkinase-ativität
|
US6316429B1
(en)
|
1997-05-07 |
2001-11-13 |
Sugen, Inc. |
Bicyclic protein kinase inhibitors
|
US6486185B1
(en)
|
1997-05-07 |
2002-11-26 |
Sugen, Inc. |
3-heteroarylidene-2-indolinone protein kinase inhibitors
|
US6228641B1
(en)
|
1997-05-20 |
2001-05-08 |
Sugen, Inc. |
Diagnosis and treatment of PTP04 related disorders
|
US6987113B2
(en)
|
1997-06-11 |
2006-01-17 |
Sugen, Inc. |
Tyrosine kinase inhibitors
|
US6342593B1
(en)
|
1997-06-11 |
2002-01-29 |
Sugen, Inc. |
Diagnosis and treatment of ALP related disorders
|
US7115710B2
(en)
|
1997-06-11 |
2006-10-03 |
Sugen, Inc. |
Diagnosis and treatment of PTP related disorders
|
US6388063B1
(en)
|
1997-06-18 |
2002-05-14 |
Sugen, Inc. |
Diagnosis and treatment of SAD related disorders
|
US6235769B1
(en)
|
1997-07-03 |
2001-05-22 |
Sugen, Inc. |
Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
|
GB9718913D0
(en)
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
US6133305A
(en)
|
1997-09-26 |
2000-10-17 |
Sugen, Inc. |
3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
|
KR100547929B1
(ko)
*
|
1997-09-26 |
2006-02-02 |
젠타리스 게엠베하 |
세린/트레오닌 단백질 키나제 기능을 조절하기 위한 아자벤즈이미다졸계 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물
|
UA71555C2
(en)
|
1997-10-06 |
2004-12-15 |
Zentaris Gmbh |
Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
|
US6531502B1
(en)
|
1998-01-21 |
2003-03-11 |
Sugen, Inc. |
3-Methylidenyl-2-indolinone modulators of protein kinase
|
US6495353B1
(en)
|
1998-01-21 |
2002-12-17 |
Sugen, Inc. |
Human orthologues of wart
|
US6514981B1
(en)
|
1998-04-02 |
2003-02-04 |
Sugen, Inc. |
Methods of modulating tyrosine protein kinase function with indolinone compounds
|
US6680170B2
(en)
|
1998-04-14 |
2004-01-20 |
Sugen, Inc. |
Polynucleotides encoding STE20-related protein kinases and methods of use
|
DE19816624A1
(de)
*
|
1998-04-15 |
1999-10-21 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
EP1082305A4
(de)
|
1998-05-29 |
2001-09-26 |
Sugen Inc |
Pyrrol substituierte 2-indolinone wirksam als proteinkinase-hemmer
|
MXPA01002173A
(es)
|
1998-08-28 |
2003-07-14 |
Scios Inc |
Inhibidores de p38-alfa cinasa.
|
EP1117397A1
(de)
*
|
1998-08-31 |
2001-07-25 |
Sugen, Inc. |
Geometrisch verhinderte 2-indolinonderivate als modulatoren der protein kinase aktivität
|
SI1115704T1
(en)
|
1998-09-25 |
2003-12-31 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes
|
US6680335B2
(en)
|
1998-09-28 |
2004-01-20 |
Sugen, Inc. |
Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
|
US6153634A
(en)
|
1998-12-17 |
2000-11-28 |
Hoffmann-La Roche Inc. |
4,5-azolo-oxindoles
|
AU771599B2
(en)
*
|
1998-12-17 |
2004-03-25 |
F. Hoffmann-La Roche Ag |
4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
|
WO2000035908A1
(en)
*
|
1998-12-17 |
2000-06-22 |
F. Hoffmann-La Roche Ag |
4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular cdk2
|
CA2354402A1
(en)
|
1998-12-17 |
2000-06-22 |
F. Hoffmann-La Roche Ag |
4,5-pyrazinoxindoles as protein kinase inhibitors
|
AU760039B2
(en)
|
1998-12-17 |
2003-05-08 |
F. Hoffmann-La Roche Ag |
4-aryloxindoles as inhibitors of JNK protein kinases
|
US6861442B1
(en)
|
1998-12-30 |
2005-03-01 |
Sugen, Inc. |
PYK2 and inflammation
|
US6624171B1
(en)
|
1999-03-04 |
2003-09-23 |
Smithkline Beecham Corporation |
Substituted aza-oxindole derivatives
|
GB9904933D0
(en)
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Compounds
|
US6492398B1
(en)
|
1999-03-04 |
2002-12-10 |
Smithkline Beechman Corporation |
Thiazoloindolinone compounds
|
US7064114B2
(en)
|
1999-03-19 |
2006-06-20 |
Parker Hughes Institute |
Gel-microemulsion formulations
|
US6689806B1
(en)
|
1999-03-24 |
2004-02-10 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
AU3770000A
(en)
*
|
1999-03-24 |
2000-10-09 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
US6541477B2
(en)
|
1999-08-27 |
2003-04-01 |
Scios, Inc. |
Inhibitors of p38-a kinase
|
CA2388599A1
(en)
|
1999-10-22 |
2001-05-03 |
Pharmacia & Upjohn Company |
Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
US6313310B1
(en)
|
1999-12-15 |
2001-11-06 |
Hoffmann-La Roche Inc. |
4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
|
PT1255536E
(pt)
|
1999-12-22 |
2006-09-29 |
Sugen Inc |
Derivados de indolinona para a modulacao da tirosina proteina cinase de tipo c-kit
|
US6620818B1
(en)
|
2000-03-01 |
2003-09-16 |
Smithkline Beecham Corporation |
Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
|
AU2001274894A1
(en)
|
2000-05-22 |
2001-12-03 |
Pharmacia And Upjohn Company |
Novel matrix metalloproteinases
|
MY128450A
(en)
|
2000-05-24 |
2007-02-28 |
Upjohn Co |
1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
CA2410509A1
(en)
|
2000-06-02 |
2001-12-13 |
Sugen, Inc. |
Indolinone derivatives as protein kinase/phosphatase inhibitors
|
AU2001271839A1
(en)
|
2000-07-05 |
2002-01-14 |
Pharmacia And Upjohn Company |
Human ion channels
|
US6504034B2
(en)
|
2001-01-23 |
2003-01-07 |
Hoffmann-La Roche Inc. |
Naphthostyrils
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
AU2002303892A1
(en)
|
2001-05-30 |
2002-12-09 |
Jingrong Cui |
5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
|
US6960572B2
(en)
*
|
2001-06-21 |
2005-11-01 |
Ariad Pharmaceuticals, Inc. |
Indolinones and uses thereof
|
DE10134196B4
(de)
*
|
2001-07-13 |
2005-08-18 |
Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt |
Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
US8034831B2
(en)
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
EP2316487B1
(de)
|
2003-04-11 |
2014-06-11 |
MedImmune, LLC |
Rekombinante IL-9 Antikörper und ihre Verwendung
|
EP1660186B1
(de)
|
2003-08-18 |
2013-12-25 |
MedImmune, LLC |
Humanisierung von antikörpern
|
CN101006076B
(zh)
*
|
2004-06-24 |
2010-09-29 |
沃泰克斯药物股份有限公司 |
Atp-结合弹夹转运蛋白的调控剂
|
US8354427B2
(en)
*
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
WO2006047639A2
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
AU2006227377B2
(en)
|
2005-03-18 |
2013-01-31 |
Medimmune, Llc |
Framework-shuffling of antibodies
|
EP1893647A2
(de)
|
2005-06-23 |
2008-03-05 |
MedImmune, Inc. |
Antikörperformulierungen mit optimierten aggregations- und fragmentierungsprofilen
|
JP2009521468A
(ja)
*
|
2005-12-24 |
2009-06-04 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Abc輸送体の調節因子としてのキノリン−4−オン誘導体
|
JP5409010B2
(ja)
|
2005-12-28 |
2014-02-05 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
N−[2,4−ビス(1,1−ジメチルエチル)−5−ヒドロキシフェニル]−1,4−ジヒドロ−4−オキソキノリン−3−カルボキサミドの固体形態
|
ES2439994T3
(es)
|
2006-08-28 |
2014-01-27 |
Kyowa Hakko Kirin Co., Ltd. |
Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
|
AU2008232902B2
(en)
|
2007-03-30 |
2013-10-03 |
Medlmmune, Llc |
Antibody formulation
|
IE20070928A1
(en)
*
|
2007-12-21 |
2009-09-30 |
Giuliani Int Ltd |
Multi target ligands
|
EP2821400B1
(de)
|
2009-03-20 |
2017-09-27 |
Vertex Pharmaceuticals Incorporated |
Verfahren zur Herstellung von CFTR-Regulatoren
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
AR085091A1
(es)
|
2011-01-26 |
2013-09-11 |
Kolltan Pharmaceuticals Inc |
Anticuerpos anti-kit y sus usos
|
CA2847527A1
(en)
|
2011-09-02 |
2013-03-07 |
Lifenet Health |
Bmp peptides & methods of use
|
MX2014010253A
(es)
|
2012-02-27 |
2014-11-12 |
Vertex Pharma |
Composicion farmaceutica y administraciones de la misma.
|
EP4063391A1
(de)
|
2012-07-25 |
2022-09-28 |
Celldex Therapeutics, Inc. |
Anti-kit-antikörper und verwendungen davon
|
CA2887129A1
(en)
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
SG10201708143QA
(en)
|
2013-06-06 |
2017-11-29 |
Pierre Fabre Médicament |
Anti-c10orf54 antibodies and uses thereof
|
PT3041507T
(pt)
|
2013-08-26 |
2021-07-26 |
Biontech Res And Development Inc |
Ácidos nucleicos que codificam anticorpos humanos para sialil-lewis
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
HUE055189T2
(hu)
|
2014-06-04 |
2021-11-29 |
Biontech Res And Development Inc |
Humán monoklonális antitestek a GD2 ganglioziddal ellen
|
EP3191186B1
(de)
|
2014-09-10 |
2021-01-27 |
Georgetown University |
Zusammensetzungen und verfahren zur verwendung von interleukin-4-induziertem gen 1 (il4i1)
|
WO2016057730A1
(en)
|
2014-10-07 |
2016-04-14 |
Strohmeier Mark |
Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
|
PL3333191T3
(pl)
|
2014-12-11 |
2021-05-04 |
Pierre Fabre Médicament |
Przeciwciała przeciwko c10orf54 i ich zastosowania
|
FI3265123T3
(fi)
|
2015-03-03 |
2023-01-31 |
|
Vasta-aineita, käyttöjä & menetelmiä
|
CN108925136B
(zh)
|
2015-12-02 |
2022-02-01 |
斯特赛恩斯公司 |
特异于糖基化的btla(b和t淋巴细胞衰减因子)的抗体
|
WO2017096051A1
(en)
|
2015-12-02 |
2017-06-08 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
KR20200015602A
(ko)
|
2017-05-31 |
2020-02-12 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
|
US20200131266A1
(en)
|
2017-05-31 |
2020-04-30 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
CN110997724A
(zh)
|
2017-06-06 |
2020-04-10 |
斯特库伯株式会社 |
使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
|
WO2019073069A1
(en)
|
2017-10-13 |
2019-04-18 |
Boehringer Ingelheim International Gmbh |
HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
|
CN112740043A
(zh)
|
2018-07-20 |
2021-04-30 |
皮埃尔法布雷医药公司 |
Vista受体
|
CN111675647B
(zh)
*
|
2020-06-26 |
2022-03-01 |
深圳技术大学 |
2-吲哚酮类pak1抑制剂及其在抗肿瘤治疗药物中的应用
|